TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented history of reduced GALNS activity relative to the normal range of the laboratory performing the assay, or documented result of molecular genetic testing confirming diagnosis of MPS IVA.~* Willing and able to provide written, signed informed consent, or in the case of subjects under the age of 16 years, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained, and prior to any research-related procedures.~* Between 5 and 18 years of age, inclusive.~* Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.~* Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study.~* Willing to perform all study procedures as physically possible.~Exclusion Criteria:~* Previous hematopoietic stem cell transplant (HSCT).~* Has known hypersensitivity to BMN 110 or its excipients.~* Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.~* Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.~* Concurrent disease or condition that would interfere with study participation or safety, including, but not limited to, symptomatic cervical spine instability.~* Any condition that, in the view of the Principal Investigator (PI), places the subject at high risk of poor treatment compliance or of not completing the study.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- BMN 110 (Type: EXPERIMENTAL): Within-patient Dose-Escalation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed mucosal or acral 2. Presence of a c-Kit mutation of exon 9, 11 or 13, or mutations Y822D and mutations D820Y, Y823D of exon 17, as confirmed by the central laboratory 3. Stage III unresectable or stage IV disease 4. The presence of one or more measurable lesions as detected by radiological or photographic methods and assessed according to RECIST 1.0. Lesions must have a size of at least 10mm at longest diameter (using a slice thickness of 5 mm)or double the slice thickness to be considered a target lesion. Target lesions should not be selected in previously irradiated fields unless there is clear evidence of progression 5. WHO performance status 0 - 2~Exclusion Criteria:~1. C-Kit mutation of exons 17(except mutations D820Y, Y822D or Y823D) or any other exon not allowed by the inclusion criteria~2. Patients with c-Kit amplifications only and no mutation~3. Patients with any history of brain metastases~4. Patients who have had any prior treatment with TKIs~5. Patients receiving medications or herbal extracts which interfere with nilotinib metabolism which are not discontinued by the time of the baseline visit~6. Acute or chronic liver or renal disease considered unrelated to melanoma~Other protocol-defined inclusion/exclusion criteria may have applied.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nilotinib (Type: EXPERIMENTAL): 400 mg twice daily
- DTIC (Type: ACTIVE_COMPARATOR): 850 mg/m2 IV every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants diagnosed with chronic hepatitis C (CHC)~* Participants with HCV genotype 1~* Participants who, at the time of the study, are referred to the Hospital Pharmacy Service to begin treatment with PEG and RBV for 48 weeks~* Available to understand and to give Informed Consent~Exclusion Criteria:~- Participants co-infected with Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEG + RBV (Standard Clinical Practice) (Type: None): Participants receive peginterferon alfa-2b (PEG) and ribavirin (RBV) in combination therapy for 48 weeks according to standard clinical practice followed by 24 weeks of observation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female participants ≥18 years old.~2. Participants with Stage V chronic kidney disease who received a kidney transplant from a deceased donor to whom they were sensitized.~3. History of prior exposure to HLA (human leukocyte antigen):~   * Prior solid organ or tissue allograft~  * Pregnancy~  * Blood transfusion~  * Prior exposure to specific donor's HLA~Exclusion Criteria:~1. Has received treatment with eculizumab at any time prior to enrolling in this study.~2. Blood type (A, B, and O blood glycoproteins-blood type) incompatible with deceased donor.~3. History of severe cardiac disease.~4. Prior splenectomy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eculizumab (Type: EXPERIMENTAL): Eculizumab 1200 milligrams (mg) was administered intravenously (IV) over 25 to 45 minutes 1 hour prior to kidney allograft reperfusion.~Eculizumab 900 mg was administered IV over 25 to 45 minutes on post-transplantation Days 1 and 7, and on post-transplantation Days 14, 21, and 28, plus or minus 2 days.~Eculizumab 1200 mg was administered IV over 25 to 45 minutes on post-transplantation Days 35, 49, and 63, plus or minus 2 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* received ≥1 treatments for age-related macular degeneration (AMD), diabetic macular edema (DME) or macula edema secondary to branch retinal vein occlusion (BRVO)~Exclusion Criteria:~* baseline diagnosis of glaucoma~* baseline IOP during last visit of greater than 21 mmHg~* ongoing use of topical medications (eg. corticosteroids)~* pseudophakic with an anterior chamber intraocular lens~* history of ocular conditions that may impact IOP (eg. pseudoexfoliation)~* previous in-office (eg. laser peripheral iridotomy) and vitreoretinal surgical procedures (eg. pars plana vitrectomy).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Brimonidine Pre-Administration During First Visit (Type: ACTIVE_COMPARATOR): None
- Brimonidine Pre-Administration During Second Visit (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult (18 or older) with deficiency in one or more IgG subclasses with documented history of recurrent infections limited to upper or lower respiratory tract, urinary, and/or skin.~Exclusion Criteria:~* Patients with panhypogammaglobulinemia or selective IgA deficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Positive IgG result for toxoplasmosis (IgG)~* Ipsilateral scars of retina compatible with previous episode of toxoplasmosis retinochoroiditis~* Unilateral active lesion of chorioretinitis~Exclusion Criteria:~* Under 18 years of age~* Immunosuppressed patients~* Use of immunosuppressive treatments~* Concomitant chorioretinitis of other causes~* Pregnancy~* Allergy to Sulfonamides

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Trimethoprim-Sulfamethoxazole (Type: ACTIVE_COMPARATOR): 1 tablet every other day, morning.
- Starch tablet (Type: PLACEBO_COMPARATOR): 1 starch tablet every other day, morning.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrolled in the Parent study, CLS1001-301, through Visit 8/Month 6~* Willing and able to provide written informed consent prior to any study procedures; willing to comply with the instructions and attend all scheduled study visits~Exclusion Criteria:~* Received additional therapy for the treatment of uveitis or prohibited medication~* Require additional therapy for the treatment of uveitis or prohibited medication at the time of the Crossover visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 4 mg CLS-TA Suprachoriodal Injection (Type: None): Those subjects randomized to the CLS-TA 4 mg arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.
- Sham procedure (Type: None): Those subjects randomized to the sham procedure arm in CLS1001-301 (NCT02595398) and who completed participation without receiving additional therapy. No study drug was administered during this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Community Self-help Using Thought Field Therapy in a Traumatised Population in Uganda: a Randomised Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Volunteers recruited from local communities, who feel that they are suffering from psychological trauma.~Exclusion Criteria:~* Minimum age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thought Field Therapy (Type: EXPERIMENTAL): Thought Field Therapy delivered by trained community leaders.
- Wait list (Type: OTHER): Delayed intervention.~No intervention prior to assessment after one week (pre-test 2). Then treated with Thought Field Therapy, and re-assessed after a further week (post-test).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have presumed pancreatic adenocarcinoma based on clinical and radiologic evaluation with identifiable tumor accessible for injection (pathologic diagnosis of pancreatic adenocarcinoma must be made prior to AdV-tk injection~* For Arm A, resectable disease. Arm B for locally advanced disease has completed accrual.~* Performance status must be ECOG 0-2~* SGOT (AST)\<3x upper limit of normal~* Serum creatinine\<2mg/dl and calculated creatinine clearance \>10ml/min~* Platelets\>100,000/mm3 and WBC\>3000/mm3 and ANC\>1500/mm3~* Must give study specific informed consent prior to enrollment~Exclusion Criteria:~* Primary hepatic dysfunction including active hepatitis but not to exclude patients due to obstructive jaundice. If obstructive jaundice is clinically significant, bilirubin should be stable or decreasing prior to enrollment.~* Evidence of clinically significant pancreatitis as determined by the investigator.~* Patients on corticosteroids or other immunosuppressive drugs~* Known HIV+ patients~* Patients with acute infections (viral, bacterial or fungal infections requiring therapy)~* Pregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy~* Evidence of distant metastatic disease at the time of enrollment or other malignancy (except squamous or basal cell skin cancers) and no prior abdominal radiation therapy or prior treatment for pancreatic cancer~* Other serious co-morbid illness or compromised organ function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A resectable (Type: EXPERIMENTAL): Arm A is for resectable tumors. The first AdV-tk course is given prior to surgery by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery again followed by 14 days of valacyclovir.
- B locally advanced (Type: EXPERIMENTAL): Arm B is for locally advanced tumors for which chemoradiation is the planned standard of care treatment. AdV-tk is delivered by CT or EUS guided injection into the tumor. The first AdV-tk injection is given prior to starting chemoradiation and the second in week 3 of chemoradiation. Both injections are followed by 14 days of valacyclovir.~Enrollment has been completed for Arm B.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sargramostim in Patients With COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥ 18 years~* Patients (or legally authorized decision maker) must provide informed consent~* Test positive for SARS-CoV-2 virus by PCR~* Admitted to hospital~* Presence of acute hypoxemia defined as (either or both)~  * saturation below 93% on ≥ 2 L/min oxygen supplementation~ * PaO2/FiO2 below 350~Exclusion Criteria:~* Patients requiring invasive (mechanical ventilation) or non-invasive (CPAP, BiPAP for hypoxemia) ventilation or ECMO (Note: oxygen supplementation using high flow oxygen systems or low flow oxygen systems would not exclude patients from this study)~* Intractable metabolic acidosis~* Cardiogenic pulmonary edema~* Hypotension requiring use of vasopressors~* Hyperferritinemia (serum ferritin ≥2,000 mcg/L)~* White blood cell count \> 50,000/mm3~* Participation in another interventional clinical trial for COVID-19 therapy~* Highly immunosuppressive therapy or anti-cancer combination chemotherapy within 24 hours prior to first dose of sargramostim~* Known or suspected intolerance or hypersensitivity to sargramostim, or any component of the product~* Previous experience of severe and unexplained side effects during aerosol delivery of any kind of medical product~* Presence of any preexisting illness that, in the opinion of the Investigator, would place the patient at an unreasonably increased risk through participation in this study~* Pregnant or breastfeeding females~* Severe or uncontrolled pulmonary comorbid conditions, including systemic steroid dependent asthma, systemic steroid dependent COPD, oxygen dependent COPD, lung transplant, known interstitial lung disease, or cystic fibrosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sargramostim Arm (Type: EXPERIMENTAL): Day 1 - 5: Sargramostim treatment in addition to standard of care for COVID-19
- Control Arm (Type: ACTIVE_COMPARATOR): Standard of care for COVID-19

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nicotine Patches in Patients With Sarcoidosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* • Symptomatic (active) granulomatous lung disease (radiographic stage II or III disease) at least 6 months after the diagnosis. This selects patients that have the chronically active variant of sarcoidosis and will likely require long-term treatment (33).~Exclusion Criteria:~* • Active smokers,~  * Previous splenectomy,~ * Those requiring high-dose immunosuppression \[i.e., ≥ 0.2 mg/kg/day prednisone (or equivalent) or \> 10 mg/week methotrexate or requires second line cytolytic agents (e.g., cyclophosphamide, azathioprine) or anti-TNF treatments (e.g., thalidomide, anti-TNF antibodies, etc.)\] to control disease activity.~ * We will also exclude patients at high risk of complications relating to the use of nicotine. This will include patients with a known intolerance of nicotine or those with active cardiac or central nervous system disease who are at higher risk of cardiac arrhythmias or seizures.~ * We will also exclude patients with extensive pulmonary fibrosis based upon lung biopsy or high resolution CT scan criterion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 2. (Type: NO_INTERVENTION): control group-no intervention
- 3 (Type: NO_INTERVENTION): Healthy control group-blood and sputum samples
- 1. (Type: EXPERIMENTAL): nicotine patch; transdermal patch 7mg, 14 mg., 21 mg. 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient has a documented clinical diagnosis of Generalized Anxiety Disorder.~* Be able to understand and comply with the requirements of the study.~* Able to understand and provide written informed consent~Exclusion Criteria:~* Patients (female) must not be pregnant or lactating~* Current or past diagnosis of stroke or transient ischemic attack (TIA).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: STABIL Study: National Study With Mircera for Maintenance of Hemoglobin Level in Dialysis Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic renal anemia;~* Continuous stable intravenous maintenance epoetin therapy during previous month;~* Regular long-term hemodialysis therapy with the same mode of dialysis for previous 3 months.~Exclusion Criteria:~* Transfusion of red blood cells during previous 2 months;~* Poorly controlled hypertension, that is, sitting blood pressure exceeding 170/100 millimeter of mercury (mmHg) despite medication;~* Significant acute or chronic bleeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete